A highly selective and specific PET tracer for imaging of tau pathologies

Journal of Alzheimer's Disease

Volumn 31, Issue 3, 2012, Pages 601-612

  Zhang, Wei ^a   Arteaga, Janna ^a   Cashion, Daniel K ^a   Chen, Gang ^a   Gangadharmath, Umesh ^a   Gomez, Luis F ^a   Kasi, Dhanalakshmi ^a   Lam, Chung ^a   Liang, Qianwa ^a   Liu, Changhui ^a   Mocharla, Vani P ^a   Mu, Fanrong ^a   Sinha, Anjana ^a   Katrin Szardenings, A ^a   Wang, Eric ^a   Walsh, Joseph C ^a   Xia, Chunfang ^a   Yu, Chul ^a   Zhao, Tieming ^a   Kolb, Hartmuth C ^a  

^a SIEMENS CORPORATE RESEARCH   (United States)

Author keywords

Alzheimer's disease; amyloid ; neurofibrillary tangles; neuroimaging; paired helical filaments; PET imaging; radiotracers; tau; tau aggregates

Indexed keywords

AMYLOID BETA PROTEIN; FLUORINE 18 T808; RADIOPHARMACEUTICAL AGENT; T808; TAU PROTEIN; UNCLASSIFIED DRUG;

ADULT; AGED; ANIMAL EXPERIMENT; ARTICLE; ASSAY; AUTORADIOGRAPHY; BINDING AFFINITY; BRAIN TISSUE; CLINICAL ARTICLE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; DRUG UPTAKE; HUMAN; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; RADIODIAGNOSTIC EQUIPMENT AND SUPPLIES; RAT; SCREENING; TAUOPATHY;

EID: 84865602256     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-2012-120712     Document Type: Article

References (48)

1. Pritchard SM, Dolan PJ, Vitkus A, Johnson VW (2011) The toxicity of tau in Alzheimer disease: Turnover, targets and potential therapeutics. J Cell Mol Med 15, 1621-1635.
2. Arriagada PV, Growdon JH, Hedley-Whyte ET, Hyman BT (1992) Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease. Neurology 42, 631-639.
3. Bierer LM, Hof PR, Purohit DP, Carlin L, Schmeidler J, Davis KL, Perl DP (1995) Neocortical neurofibrillary tangles correlate with dementia severity in Alzheimer's disease. Arch Neurol 52, 81-88.
4. Dickson DW (1997) Neuropathological diagnosis of Alzheimer's disease: A perspective from longitudinal clinicopathological studies. Neurobiol Aging 18 (Suppl 1), S21-S26. (Pubitemid 27454692)
5. Lai MKP, Chen CP, Hope T, Esiri MM (2010) Hippocampal neurofibrillary tangle changes and aggressive behaviour in dementia. Neuroreport 21, 1111-1115.
6. Lee HG, Perry G, Moreira PI, Garrett MR, Liu Q, Zhu X, Takeda A, Nunomura A, Smith MA (2005) Tau phosphorylation in Alzheimer's disease: Pathogen or protector? Trends Mol Med 11, 164-169.
7. Braak H, Braak E (1991) Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 82, 239-259.
8. Ohm TG, Müller H, Braak H, Bohl J (1995) Close-meshed prevalence rates of different stages as a tool to uncover the rate of Alzheimer's disease-related neurofibrillary changes. Neuroscience 64, 209-217.
9. Bulic B, Pickhardt M, Mandelkow EM, Mandelkow E (2010) Tau protein and tau aggregation inhibitors. Neuropharmacology 59, 276-289.
10. Ashford JW, Soultanian NS, Zhang S-X, Geddes JW (1998) Neuropil threads are collinear with MAP2 immunostaining in neuronal dendrites of Alzheimer brain. J Neuropathol Exp Neurol 57, 972-978. (Pubitemid 28478007)
11. Mangialasche F, Solomon A, Winblad B, Mecocci P, Kivipelto M (2010) Alzheimer's disease: Clinical trials and drug development. Lancet Neurol 9, 702-716.
12. Rafii MS (2010) The pulse of drug development for Alzheimer's disease. Rev Recent Clin Trials 5, 57-62.
13. Abhilash KD, Pratap C (2009) Tau-based therapies for Alzheimer's disease:Wave of the future? Primary Psychiatry 16, 40-46.
14. Brunden KR, Trojanowski JQ, Lee VM-Y (2009) Advances in tau-focused drug discovery for Alzheimer's disease and related tauopathies. Nat Rev Drug Discov 8, 783-793.
15. Ott BR, Cohen RA, Gongvatana A, Okonkwo OC, Johanson CE, Stopa EG, Donahue JE, Silverberg GD (2010) Alzheimer's Disease Neuroimaging Initiative. J Alzheimers Dis 20, 647-657.
16. Wallin AK, Blennow K, Andreasen N, Minthon L (2006) CSF biomarkers for Alzheimer's Disease: Levels of beta-amyloid, tau, phosphorylated tau relate to clinical symptoms and survival. Dement Geriatr Cogn Disord 21, 131-138. (Pubitemid 43201321)
17. Buchhave P, Minthon L, Zetterberg H, Wallin K, Blennow K, Hansson O (2012) Cerebrospinal fluid levels of β-amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia. Arch Gen Psychiatry 69, 98-106.
18. Ashford JW, Salehi A, Furst A, Bayley P, Frisoni GB, Jack CR Jr, Sabri O, Adamson MM, Coburn KL, Norbert Schuff OJ, Spielman D, Edland SD, Allyson Rosen BS, Kennedy D, Weiner M, Perry G (2011) Introduction: Imaging the Alzheimer brain. J Alzheimers Dis 26 (Suppl 3), 1-27.
19. Herholz K, Ebmeier K (2011) Clinical amyloid imaging in Alzheimer's disease. Lancet Neurol 10, 667-670.
20. Vallabhajosula S (2011) Positron emission tomography radiopharmaceuticals for imaging brain beta-amyloid. Semin Nucl Med 41, 283-299.
21. Shin J, Kepe V, Barrio JR, Small GW (2011) The merits of FDDNP-PET imaging in Alzheimer's disease. J Alzheimers Dis 26 (Suppl 3), 135-145.
22. Klunk WE, Engler H, Nordberg A, Wang Y, Blomqvist G, Holt DP, Bergstrom M, Savitcheva I, Huang G-F, Estrada S, Ausen B, Debnath ML, Barletta J, Price JC, Sandell J, Lopresti BJ, Wall A, Koivisto P, Antoni G, Mathis CA (2004) Imaging brain amyloid in Alzheimer's disease using the novel PET tracer PIB. Ann Neurol 55, 306-319. (Pubitemid 38269583)
23. Vandenberghe R, Van Laere K, Ivanoiu A, Salmon E, Bastin C, Triau E, Hasselbalch S, Law I, Andersen A, Korner A, Minthon L, Garraux G, Nelissen N, Bormans G, Buckley C, Owenius R, Thurfjell L, Farrar G, Brooks DJ (2010) 18Fflutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: A phase 2 trial. Ann Neurol 68, 319-329.
24. Johnson AE, Jeppsson F, Sandell J, Wensbo D, Neelissen JA, Juŕeus A, Str̈om P, Norman H, Farde L, Svensson SP (2009) AZD2184: A radioligand for sensitive detection of beta-amyloid deposits. J Neurochem 108, 1177-1186.
25. Verhoeff NP, Wilson AA, Takeshita S, Trop L, Hussey D, Singh K, Kung HF, Kung MP, Houle S (2004) In vivo imaging of Alzheimer disease β-amyloid with [11C]SB-13 PET. Am J Geriatr Psychiatry 12, 584-595. (Pubitemid 41031060)
26. Barthel H, Sabri O (2011) Florbetaben to trace amyloid-β in the Alzheimer brain by means of PET. J Alzheimers Dis 26 (Suppl 3), 117-121.
27. Kolb HC, Walsh JC, Zhang W, Gangadharmath UB, Kasi D, Chen K, Sinha A, Wang E, Chen G, Mocharla VP, Scott PJH, Padgett HC, Liang Q, Gao Z, Zhao T, Xia C (2010) Imaging agents useful for identifying AD pathology. PCT Int Appl WO2010011964.
28. Clark CM, Schneider JA, Bedell BJ, Beach TG, Bilker WB, Mintun MA, Pontecorvo MJ, Hefti F, Carpenter AP, Flitter ML, Krautkramer MJ, Kung HF, Coleman RE, Doraiswamy PM, Fleisher AS, Sabbagh MN, Sadowsky CH, Reiman EP, Zehntner SP, Skovronsky DM (2011) Use of florbetapir-PET for imaging beta-amyloid pathology. JAMA 305, 275-283.
29. FDA Press Release, April 10, 2012, http://www.fda.gov/NewsEvents/ Newsroom/PressAnnouncements/ucm299678. htm.
30. Aizenstein HJ, Nebes RD, Saxton JA, Price JC, Mathis CA, Tsopelas ND, Ziolko SK, James JA, Snitz BE, Houck PR, Bi W, Cohen AD, Lopresti BJ, DeKosky ST, Halligan EM, Klunk WE (2008) Frequent amyloid deposition without significant cognitive impairment among the elderly. Arch Neurol 65, 1509-1517.
31. Fodero-Tavoletti MT, Okamura N, Furumoto S, Mulligan RS, Connor AR, McLean CA, Cao D, Rigopoulos A, Cartwright GA, O'Keefe G, Gong S, Adlard PA, Barnham KJ, Rowe CC, Masters CL, Kudo Y, Cappai R, Yanai K, Villemagne VL (2011) 18F-THK523: A novel in vivo tau imaging ligand for Alzheimer's disease. Brain 134, 1089-1100.
32. Rojo LE, Alzate-Morales J, Saavedra IN, Davies P, Maccioni RB (2010) Selective interaction of lansoprazole and astemizole with tau polymers: Potential new clinical use in diagnosis of Alzheimer's disease. J Alzheimers Dis 19, 573-589.
33. Villemagne VL, Furumoto S, Fodero-Tavoletti MT, Pejoska S, Kudo Y, Mulligan RS, Hodges J, Masters CL, Yanai K, Rowe CC, OkamuraN (2012) In vivo tau imaging. 6th Human Amyloid Imaging Conference, January 12-13, 2012, Miami Florida, p. 43.
34. Szardenings AK, Zhang W, Kolb HC, Cashion DK, Chen G, Kasi D, Lui C, Sinha A, Wang E, Yu C, Gangadharmath UB, Walsh JC (2011) Imaging agents for detecting neurological disorders. US Patent Appl US20110182812.
35. Hill J (2003) In vitro drug metabolism using liver microsomes. Curr Protocols Pharmacol, 7.8.1-7.8.11.
36. Collins TJ (2007) ImageJ for microscopy. BioTechniques 43 (S1), S25-S30.
37. Cold Spring Harbor Laboratory (image sourced from the 3D Brain, www.g2conline.org by DNA Learning Center: www.dnalc.org) (accessed February 1, 2011).
38. Arnold SE, Hyman BT, Flory J, Damasio AR, Van Hoesen GW (1991) The topographical and neuroanatomical distribution of neurofibrillary tangles and neuritic plaques in the cerebral cortex of patients with Alzheimer's disease. Cereb Cortex 1, 103-116.
39. Rizzo G, Martinelli P, Manners D, Scaglione C, Tonon C, Cortelli P, Malucelli E, Capellari S, Testa C, Parchi P, Montagna P, Barbiroli B, Lodi R (2008) Diffusion-weighted brain imaging study of patients with clinical diagnosis of corticobasal degeneration, progressive supranuclear palsy and Parkinson's disease. Brain 131, 2690-2700.
40. Wang LN, Zhu MW, Feng YQ, Wang JH (2006) Pick's disease with Pick bodies combined with progressive supranuclear palsy without tuft-shaped astrocytes: A clinical, neuroradiologic and pathological study of an autopsied case. Neuropathology 26, 222-230.
41. Dickson DW, Bergeron C, Chin SS, Duyckaerts C, Horoupian D, Ikeda K, Jellinger K, Lantos PL, Lippa CF, Mirra SS, Tabaton M, Vonsattel JP, Wakabayashi K, Litvan I, Office of Rare Diseases of the National Institutes of Health (2002) Office of Rare Diseases neuropathologic criteria for corticobasal degeneration. J Neuropathol Exp Neurol 61, 935-946. (Pubitemid 35278715)
42. Búee-Scherrer V, Búee L, Hof PR, Leveugle B, Gilles C, Loerzel AJ, Perl DP, Delacourte A (1995) Neurofibrillary degeneration in amyotrophic lateral sclerosis/parkinsonismdementia complex of Guam. Immunochemical characterization of tau proteins. Am J Pathol 146, 924-932.
43. Goedert M, Jakes R (2005) Mutations causing neurodegenerative tauopathies. Biochim Biophys Acta 1739, 240-250. (Pubitemid 40021808)
44. McKee AC, Gavett BE, Stern RA, Nowinski CJ, Cantu RC, Kowall NW, Perl DP, Hedley-Whyte ET, Price B, Sullivan C, Morin P, Lee H-S, Kubilus CA, Daneshvar DH, Wulff M, Budson AE (2010) TDP-43 proteinopathy and motor neuron disease in chronic traumatic encephalopathy. J Neuropathol Exp Neurol 69, 918-929.
45. Buerger K, Alafuzoff I, Ewers M, Pirttil̈a T, Zinkowski R, Hampel H (2007) No correlation between CSF tau protein phosphorylated at threonine 181 with neocortical neurofibrillary pathology in Alzheimer's disease. Brain 130, e82.
46. Spies PE, Claassen JAHR, Slats D, Olde Rikkert MGM, Verbeek MM, Kessels RPC (2010) Cerebrospinal fluid tau and amyloid beta proteins do not correlate with cognitive functioning in cognitively impaired memory clinic patients. CNS Spectr 15, 588-593.
47. Honson NS, Johnson RL, Huang W, Inglese J, Austin CP, Kuret J (2007) Differentiating Alzheimer disease-associated aggregates with small molecules. Neurobiol Dis 28, 251-260. (Pubitemid 350116597)
48. Crowe A, Ballatore C, Hyde E, Trojanowski JQ, Lee VM (2007) High throughput screening for small molecule inhibitors of heparin-induced tau fibril formation. Biochem Biophys Res Commun 358, 1-6. (Pubitemid 46719073)